Priscilla Chan charts an ambitious, unglamorous course to fight disease. (Her husband is involved, too.)
SAN FRANCISCO — Dr. Priscilla Chan was just over a year out of her pediatric…
Author: STAT
STAT Plus: With new combination drug data, Exelixis takes another shot at prostate cancer treatment
In 2014, the Bay Area biotech company Exelixis (EXEL) tried to develop a drug for…
STAT Plus: Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab
As U.S. regulators consider whether to approve the first new treatment for Alzheimer’s disease in…
Trump doesn’t want the FDA to regulate tobacco
The Trump administration is proposing to strip the Food and Drug Administration of all authority…
STAT Plus: For homebound people and their distant caregivers, smarter speakers to keep track of their health
Every day, Kathleen McVicar of Cotuit, Mass., has a few simple questions for her 85-year-old…
STAT Plus: Pharmalittle: Two more Alzheimer’s drugs fail in studies; how Democratic candidates differ on lowering drug costs
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
.jpg)
Opinion: 10 reasons why health care startups fail
In our roles at MedTech Innovator, a global accelerator for medtech startups, we’ve worked with…
Opinion: Armchair philosophizing doesn’t help conscious patients in vegetative states
“Imagine.” This word let a severely brain injured patient tell neuroscientists she was still conscious…
In their words: Warren, Buttigieg, Klobuchar, and other Democrats explain exactly how they’d lower drug prices
Every single Democratic presidential candidate agrees that the federal government should take a far more…
Fluctuating funding and flagging interest hurt coronavirus research, leaving crucial knowledge gaps
Journalists covering the emergence and spread of the new coronavirus in China are awash with…
The vodka trial: In search of a treatment for vocal disorders, a researcher puts patient anecdotes to the test
Mondays are vodka days. For the members of Dr. Kristina Simonyan’s lab, this is not…
STAT Plus: Investor impatience with Gilead reclamation project sparks acquisition chatter
In recent days, there’s been investor chatter about stalled-out Gilead Sciences (GILD) becoming a takeover…
WHO cautions that transmission of the new coronavirus outside of China could increase
The World Health Organization’s director-general cautioned Saturday that transmission of the new coronavirus outside of…
.jpg)
‘We’re definitely not prepared’: Africa braces for new coronavirus
LUSAKA, Zambia — At a Chinese-run hospital in Zambia, some employees watched as people who…
Coronavirus concerns trigger global run on supplies for health workers, causing shortages
Concern about the new coronavirus spreading in China has triggered a run on global supplies…
FDA approves AI-based software that helps doctors take ultrasound pictures of the heart
The Food and Drug Administration has approved a software product from an artificial intelligence startup…
STAT Plus: California scolds McKesson for supplying excessive controlled substances to a children’s pharmacy
The California Board of Pharmacy is accusing McKesson (MCK), the large pharmaceutical wholesaler, of selling…
Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share…
STAT Plus: A closer look at Bernie Sanders’ plans to upend pharma and lower drug prices
The following is an excerpt from STAT’s deep dive report into the Democrats running for…
Opinion: To maximize progress in global health, invest more in community health workers
Anna Mzeru’s day shifts as a nurse in a clinic in the Bagamoyo region of…
STAT Plus: Pharmalittle: Novartis lottery for gene therapy begins amid tough questions; coronavirus vaccine may take a year
And so, another working week will soon draw to a close. Not a moment too…
Opinion: I was fortunate to get post-23andMe genetic counseling. Everyone should have that option
A year ago, I was shivering in the pre-op room at Cedars-Sinai Medical Center waiting…
As medical professionals, my husband and I know the Nigerian travel ban is cruel. Now the pain is personal
A few days ago my daughter was diagnosed with a rare disease. In our time…
‘We need everyone for this’: U.S. hospitals harnessing resources to brace for any spike in coronavirus cases
When the H1N1 flu began spreading a decade ago, U.S. hospitals were flooded with patients….
A lottery like no other offers up a cutting-edge medicine — with lives on the line
The lottery that began this week was not about money, or about choosing a school,…
Listen: Fake outbreak news, treating coronavirus, and biotech’s Mount Rushmore
Is peer review underrated? Can biotech stop an outbreak? And would you mind giving us…
STAT Plus: U.S. officials lash out at the Dutch government for moves that ‘undermine’ pharma patent rights
In an unusual move, the U.S. Embassy in the Netherlands is taking the Dutch government…
STAT Plus: Beam Therapeutics raises $180 million in IPO
Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public…
STAT Plus: Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead
Rise and shine, everyone, another busy day is on the way. We can tell because…
Opinion: We need better regulation of stem cell therapies, especially rogue clinics
Rogue stem cell clinics continue to victimize hopeful patients seeking cures for cancer, Parkinson’s disease,…
Opinion: Open science, publishing, and public research support: Could Trump have it right?
In the three years since Donald Trump was inaugurated as president, I have rarely supported…
In effort to develop coronavirus vaccine, outbreak expert sees ‘hardest problem’ of his career
As China struggles to contain an epidemic caused by a new coronavirus, science is racing…
STAT Plus: Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so
Move aside, Big Tech. If 2017 was the year technology giants like Apple set their…
Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases
Jeffrey Bluestone, the prominent immunologist, has decided to leave his position as president of the…
Sanofi reports positive results on multiple sclerosis drug licensed from Principia
The French drug giant Sanofi on Thursday reported positive results in a study of its…
STAT Plus: Years later, raw clinical trial data tells us the extent of Avandia’s heart risks
File this under “What a difference patient-level data can make.” In 2007, controversy flared over…
Juul and other e-cig makers to Congress: FDA, not you, should regulate us
WASHINGTON — When the CEOs from Juul and four other leading e-cigarette makers came before…
STAT Plus: A closer look at Pete Buttigieg’s aggressive, wonky plan to lower drug prices
The following is an excerpt from STAT’s deep dive report into the Democrats running for…
Biogen wins patent challenge to key multiple sclerosis drug
A U.S. appeals panel on Wednesday denied a patent challenge against Biogen’s multiple sclerosis drug…
A conversation with cancer researcher Charles Sawyers, winner of the first STAT Biomedical Innovation Award
Over a career spanning more than three decades, Dr. Charles Sawyers played a key role in…
STAT Plus: Gilead loses its challenge to a pair of U.S. patents over an HIV prevention pill
In a setback to Gilead Sciences (GILD), a federal panel rejected its bid to invalidate…
Opinion: Novel coronavirus 2019-nCoV exposes a flaw in the Nagoya Protocol
As the number of people infected with the novel coronavirus 2019-nCoV increases each day, scientists…
STAT Plus: Pharmalittle: Trump claims on drug prices are mostly false; Merck to spin off old drugs into new company
Good morning, everyone, and welcome to the middle of the week, which arrived rather quickly,…
Merck to spin off new $6.5 billion firm focused on women’s health, older drugs
Merck said Wednesday that it will create a new drug company to sell many of…
STAT Plus: New ‘real world evidence’ company leverages medical societies to produce data for pharma
Two years ago, Roche spent $1.9 billion to buy a startup, Flatiron Health, which uses…
STAT Plus: This biotech just bought three failed drugs. Here’s why
Biopharma companies don’t usually buy experimental drugs that don’t work. But that’s exactly what CODA…
Chatbots are screening for the new coronavirus — and turning up cases of the flu
SAN FRANCISCO — As the new coronavirus spreads, health-tech startups with medical chatbots are scrambling…
Opinion: In hospitals, housekeepers are truly the ‘keepers of the house’
Malcolm cleans patient rooms and offices in the large medical center where we both work…
In the race to develop a coronavirus treatment, Regeneron thinks it has the inside track
TARRYTOWN, N.Y. — The novel coronavirus arrived at Regeneron Pharmaceuticals’ sprawling campus like any other…
STAT Plus: 4 ways Walmart is hoping its retail savvy can overhaul the health care system
Walmart made waves in September when it announced an ambitious plan to create new, freestanding…